Why a Single hsCRP Reading May Not Tell the Full Story for Heart Risk

Cardiovascular disease remains the leading cause of death globally, and inflammation has emerged as a critical driver beyond traditional risk factors like cholesterol and blood pressure. High-sensitivity C-reactive protein (hsCRP) has become one of the most accessible and frequently used biomarkers for assessing inflammatory cardiovascular risk, appearing in guidelines and clinical practice worldwide. Yet a new commentary in the European Heart Journal raises an important caution: a single hsCRP measurement may not capture enough information to reliably stratify a patient's risk.

The commentary, authored by Han J from Yangming Hospital Affiliated to Ningbo University, argues that hsCRP is inherently variable. Transient events such as minor infections, physical stress, or recent exercise can temporarily elevate levels, while chronic low-grade inflammation may occasionally produce normal single readings. This biological noise means that one data point can mislead clinicians into over- or under-estimating a patient's cardiovascular inflammatory burden.

The author advocates for moving beyond single-timepoint measurement toward strategies that account for hsCRP variability over time. This may include serial measurements, averaging multiple readings, or integrating hsCRP trends with other clinical and biomarker data. Such an approach would more accurately reflect an individual's baseline inflammatory state and its trajectory.

For clinicians, this has direct implications in risk-stratification workflows, particularly when deciding whether to initiate or escalate anti-inflammatory or statin therapy. For patients actively monitoring their own biomarkers, it underscores the importance of not overreacting to a single lab value without contextual interpretation.

Caveats are notable: this is a commentary rather than an original research study, meaning the arguments are largely expert opinion and synthesis rather than new empirical data. The full text was not available for review, limiting assessment of the evidence cited. Nonetheless, the core message — that dynamic, longitudinal biomarker monitoring is superior to static single-point measurement — aligns with broader trends in precision cardiovascular medicine.